Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic α2A-adrenergic receptor

PLoS One. 2013 May 14;8(5):e63622. doi: 10.1371/journal.pone.0063622. Print 2013.

Abstract

Myocardial depression is an important contributor to mortality in sepsis. We have recently demonstrated that α2-adrenoceptor (AR) antagonist, yohimbine (YHB), attenuates lipopolysaccharide (LPS)-induced myocardial depression. However, the mechanisms for this action of YHB are unclear. Here, we demonstrated that YHB decreased nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) levels in the myocardium and plasma, attenuated cardiac and hepatic dysfunction, but not kidney and lung injuries in endotoxemic mice. Immunohistochemical analysis revealed that cardiac α2A-AR was mostly located in sympathetic nerve presynaptic membrane; YHB decreased cardiac α2A-AR level and promoted cardiac norepinephrine (NE) release in endotoxemic mice. Reserpine that exhausted cardiac NE without markedly decreasing plasma NE level abrogated the inhibitory effects of YHB on cardiac TNF-α and iNOS expression as well as cardiac dysfunction, but not the suppressive effects of YHB on plasma TNF-α and NO elevation in LPS-challenged mice. Furthermore, both reserpine and YHB significantly inhibited LPS-induced myocardial apoptosis. α1-AR, β2-AR, but not β1-AR antagonists reversed the inhibitory effect of YHB on LPS-stimulated myocardial apoptosis. However, β1-AR antagonist attenuated LPS-caused cardiomyocyte apoptosis, partly abolished the protective effect of YHB on the left ventricular ejection fraction in endotoxemic mice. Altogether, these findings indicate that YHB attenuates LPS-induced cardiac dysfunction, at least in part, through blocking presynaptic α2A-AR and thus increasing cardiac NE release. YHB-elevated cardiac NE improves cardiac function via suppressing cardiac iNOS and TNF-α expression, activating β1-AR and inhibiting cardiomyocyte apoptosis through α1- and β2-AR in endotoxemic mice. However, cardiac β1-AR activation promotes LPS-induced cardiomyocyte apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-2 Receptor Antagonists / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Heart / drug effects*
  • Heart / metabolism*
  • Heart / physiopathology
  • Lipopolysaccharides / pharmacology*
  • Liver / drug effects
  • Liver / physiopathology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Nitric Oxide / biosynthesis
  • Norepinephrine / metabolism*
  • Organ Specificity
  • Presynaptic Terminals / drug effects
  • Protein Transport / drug effects
  • Receptors, Adrenergic, alpha-2 / metabolism*
  • Reserpine / pharmacology
  • Synapses / drug effects
  • Synapses / metabolism*
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Yohimbine / pharmacology*

Substances

  • Adrenergic alpha-2 Receptor Antagonists
  • Lipopolysaccharides
  • Receptors, Adrenergic, alpha-2
  • Tumor Necrosis Factor-alpha
  • Yohimbine
  • Nitric Oxide
  • Reserpine
  • Norepinephrine

Grants and funding

This study was supported by grants from the National Natural Science Foundation of China (81170222 and 30971191), the Guangdong Natural Science Foundation (S2011020005408), and fundamental Research Funds for the Central Universities (21611403). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.